GlassScriptPhysician profile
Lovin George
NPI 1760036065
$2,825.71
in general payments reported to CMS, 2019-2025
29 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $379 · 2023: $174 · 2024: $760 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.44 |
| Education | $307.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.01 | 2022-2025 | |
| Astellas Pharma US INC | $289.88 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $277.10 | 2022-2023 | Opdivo, Camzyos |
| Astrazeneca Pharmaceuticals LP | $215.84 | 2024-2025 | Airsupra, Breztri, Tezspire |
| Regeneron Healthcare Solutions, INC. | $165.87 | 2024-2025 | Dupixent |
| Harmony Biosciences LLC | $163.07 | 2024-2025 | |
| Gilead Sciences, INC. | $153.79 | 2022-2024 | Epclusa |
| Glaxosmithkline, LLC. | $121.47 | 2024-2025 | Nucala |
| Janssen Biotech, INC. | $91.28 | 2024-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $85.58 | 2024-2025 | Sucraid, Sucraid |
| Baxter Healthcare | $73.49 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $71.93 | 2025 | Arikayce |
| Lilly USA, LLC | $70.35 | 2024-2025 | Mounjaro, Zepbound, Omvoh |
| Merck Sharp & Dohme LLC | $67.50 | 2024-2025 | Pifeltro, Prevymis, Zerbaxa |
| Melinta Therapeutics, LLC | $63.45 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $61.69 | 2024-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $60.00 | 2022 | |
| United Therapeutics Corporation | $54.13 | 2025 | Tyvaso |
| Ardelyx, INC. | $47.30 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.99 | 2025 | Ofev |
| Pfizer INC. | $27.03 | 2022 | |
| Phathom Pharmaceuticals, INC. | $24.63 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $22.50 | 2025 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $21.42 | 2025 | Eohilia |
| Vertex Pharmaceuticals Incorporated | $19.80 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.80 | 2025 | |
| Pharmacosmos Therapeutics INC. | $17.79 | 2024 | Monoferric |
| Aimmune Therapeutics, INC. | $17.39 | 2024 | |
| Intercept Pharmaceuticals, INC. | $16.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lovin George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.